Tender detail
Conclusion of a non-exclusive rebate agreement for abobotulinumtoxin A medicines for 2026–2028
Summary
DAK-Gesundheit is procuring non-exclusive pharmaceutical rebate agreements for the active substance botulinum toxin type A, limited to abobotulinum (ATC M03AX21). The agreements cover medicines identified by the supplier and run from 1 December 2026 to 30 November 2028, or end earlier when a new exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.